A Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulation Factor VIII Fc - Von Willebrand Factor - XTEN Fusion Protein (rFVIIIFc-VWF-XTEN) (BIVV001) in Previously Treated Adults With Severe Hemophilia A (EXTEN-A)

NCT03205163 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Hemophilia A

Interventions

BIOLOGICAL: Advate (Low Dose)
BIOLOGICAL: Advate (High Dose)
BIOLOGICAL: BIVV001 (Low Dose)
BIOLOGICAL: BIVV001 (High Dose)

Sponsor

Bioverativ, a Sanofi company